ABCG2 and glioblastoma: However, rucaparib’s lack of ability to traverse the blood-brain barrier (BBB), coupled with its vulnerability to transporters like P-glycoprotein and breast cancer resistance protein (BCRP), limits its clinical effectiveness in glioblastoma [16].